Clinical Trial to Evaluate the Efficacy of Echinochrome A, An Active Principle of Sea Urchin Eggs, in Improving Quality of Life and Reducing Cellular Inflammation in Long Covid Patients

Le résumé fourni par la source

Introduction: The global impact of COVID-19 has resulted in a long COVID syndrome, which is defined by persistent symptoms and a significant decline in patients’ quality of life. To address this challenge, we conducted a multicenter, double-blind, randomized study to assess the effects of Echinochrome A, the active principle from sea urchin found in the dietary supplement Echa Marine®, on health-related quality of life and inflammatory biomarkers in 50 long-term COVID patients. Baseline characteristics were similar between groups. Methods: Adult men and non-pregnant women aged 18 to 60 diagnosed with long COVID were randomly assigned to the intervention or control groups. For three months, patients were given daily doses of EchA Marine®, a dietary supplement made from sea urchin eggs, or a matching placebo. The effects of EchA Marine® were assessed using the EuroQol 5-Dimension (EQ-5D) questionnaire and serum parameter measurements. Discussion: Consumers of EchA Marine®exhibited significant reductions in pain, improved mobility, enhanced overall quality of life, and improved inflammation biomarkers. These findings suggest that Echinochrome A, due to its antioxidant and anti-inflammatory properties, effectively alleviates long COVID symptoms, particularly pain and mobility. The results underscore the potential of EchA Marine® as a safe and natural remedy for long COVID patients, warranting further research with larger cohorts to consolidate its efficacy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.